HL-A antigens were determined retrospectively in a group of 14 surgically cured bronchogenic carcinoma patients and prospectively in another group of 100 untreated patients. In the retrospective group, the frequencies of antigens W-19 and HL-A5 were significantly increased when compared with the noncancer control and the prospective lung cancer populations. In the latter group, 60% of the patients with W-19 and 58% with HL-A5 survived without evidence of tumor for at least 1 year after treatment compared with 15% of patients with neither of these antigens, Pless than 0.01 and 0.005, respectively. These comparisons were for adenocarcinoma and squamous carcinoma. The patient groups for oat cell and undifferentiated carcinoma were too small for valid statistical comparisons. This preliminary study suggests that the presence of HL-A antigens W-19 and HL-AS confers resistance to dissemination of bronchogenic carcinoma.-J Natl Cancer Inst 54: 1283-1286, 1975.
CERTAIN HL-A ANTIGENS have been associated with long-term survival in patients with acute lymphocytic leukemia (1, 2) , and the antigen HL-A8 has been related to prolonged survival in Hodgkin's disease (3) . Recognition of the association between immune responsiveness and histocompatibility antigens (4) and between susceptibility to oncogenic virus and histocompatibility antigens (5) has encouraged widespread searching for similar relationships in humans between diseases with immunologic manifestations and the HL-A human leukocyte antigens (6) (7) (8) (9) (10) . An extensive investigation of the HL-A frequencies associated with a wide variety of solid tumors has failed to demonstrate any antigen that may be related to increased susceptibility to these cancers (11) .
The purpose of this study was to investigate the possible correlation of HL-A antigens with prolonged survival in patients with bronchogenic carcinoma. A group of 14 cured bronchogenic carcinoma patients were studied retrospectively for HL-A antigen type and another group of 100 patients undergoing treatment for bronchogenic carcinoma were studied prospectively. Data relating survival, tumor histology, and HL-A typing are analyzed.
MATERIALS AND METHODS
Patients.-Retrospective group: 14 Caucasian patients surgically treated for bronchogenic carcinoma were evaluated; 9 had squamous carcinoma, 5 had adenocarcinoma. They averaged 6.2 years after treatment (range, 3-10 yr) and were considered cured of their cancer.
Prospective group.-Of the 100 Caucasian patients with bronchogenic carcinoma who were examined, 38 had squamous carcinoma, 32 had adenocarcinoma, 20 had oat cell carcinoma, and 10 had undifferentiated carcinoma. These patients were evaluated before or shortly after either surgery or radiation therapy.
HL-A typing.-HL-A typing was done with a lymphocyte microcytotoxicity test and antisera defining 21 specificities (12) . The W-19 specificity was defined by two antisera, Thompson (NIH #2-50-6-04-13-02) and Thompson (NIH #2-50-6-04-21-01) . These were different bleedings from the same subject and probably recognize only a part of the complex W-19 specificity (13). A control population of 184 healthy adult Caucasians of both sexes, obtained through the Clinical Center Blood Bank and from laboratory personnel, who had a negative his wry for malignancy, were tested concurrently.
Statistical analysis.-HL-A antigen frequencies were compared between the retrospective, prospective, and control populations by means of chisquare analysis with Yates correction for small sample .size (14) , although it was recognized that this gives perhaps too conservative an estimate. Each probability value (P) herein reported should be multiplied by a factor of 21 (the number of antigens studied) to correct for the selection of an antigen frequency occurring as an extreme, by chance alone, when this large a number of antigens is examined. The P values are reported uncorrected both to facilitate comparison of these values with subsequent investigations and because of the retrospective-prospective design of this study (15) .
"Prolonged survival" after treatment was defined for the prospective group as being alive and without evidence of tumor at 1 year after surgery and/or radiation therapy, since, at intervals greater than 1 year after therapy, the almost exponential decline in the survival curve for bronchogenic carcinoma begins to level off (16, 17) . All but one of the prospectively studied patients were followed for at least 1 year after therapy. Survival in this group was analyzed by tumor histology, because prognosis for oat cell and undifferentiated carcinoma is generally considered to be poorer than for squamous carcinoma and adenocarcinoma (18, 19) .
RESULTS

Retrospective Group
HL-A frequencies in patients cured of bronchogenic carcinoma differed from those of both the lung cancer patients prospectively tested and the noncancer controls, in that the frequencies of W-19 and HL·A5 were significantly increased (table 1) . W·19 was present in 36'70 of cured patients in contrast to 10% in the prospective group (P<O.025) and 11% in the controls (P<O.025). HL-A5 was present in 43'70 of cured patients in contrast to 17% in the prospective group (P<O.lO) and 12% in the controls (p<O.OI). Ten of the 14 cured patients (71%) had either W-19 o~ HL-A5, or both, as compared with 17'70 of the controls. No other antigens were either significantly increased or decreased in frequency from the controls.
When analyzed for the cross-reactive HL-AIOjW-19 specificities (2,(), 42% of the cured patients were positive for one or both of these antigens. When analyzed for the cross-reactive HL-A5 jW-5 specificities (part of the larger 4C cross-reactivity) , 56'70 of the patients were positive for these antigens. Eighty-six percent of the cured patients had an antigen from one or both of these cross-reactive groups in contrast to 47'70 of the prospective group (p<O.02) and 47% of the control group (p<O.02) .
When all the above P values were multiplied by 21, they lost significance. Thus we could draw no firm conclusions fr~m the study of antigen frequencies in this small group. However, the study did suggest that a characteristic of many long-term survivors of bronchogenic carcinoma was the possession of W-19 or HL-A5. We therefore hypothesized that the presence of one or more of these two antigens would be associated with prolonged survival in a prospectively studied group of patients.
Prospective Group
There was neither a significant increase nor decrease in the antigen frequencies of the prospectively studied patient group when compared with the controls, regardless of tumor histology (table  1) . Since HL-A typing was done at the time of diagnosis, this implied that HL-A antigens were not associated with susceptibility to bronchogenic carcinoma.
Survival patterns at 1 year after treatment for this group of patients are presented in table 2. The data in this table relate the survival patterns in each histologic category to HL-A type. Only W-19 and HL-A5 were associated with long-term survival and only in squamous carcinoma and adenocarcinoma. Analysis of survival patterns after treatment of oat cell and undifferentiated carcinoma in relationship to W-19 and HL-A5 was not possible because of our small sample size.
Since the pattern of survival according to HL-A type was nearly identical for our patients with squamous carcinoma and adenocarcinoma, these table 3 did not have to be corrected for the number of antigens assayed, because their specific study was based on predictions from the retrospective group.
DISCUSSION
Our most important finding is the association of the HL-A antigens W-19 and HL-A5 with prolonged survival in patients with bronchogenic carcinoma. In the retrospective analysis of cured bronchogenic carcinoma patients, the frequencies of W-19 and HL-A5 were increased when compared with the controls and the prospective group. Eightysix percent of the cured patients had either one of these antigens or one of their cross-reacting specificities, HL-AlO and W-5. In the prospective analysis, patients with either W-19 or HL-A5 had a significantly increased chance of long-term survival. This suggests that there is a factor(s) associated with certain antigens of both the first and second segregant series of HL-A antigens that confers some form of resistance to dissemination of bronchogenic carcinoma. It is tempting to speculate that this factor is an HL-A-linked immune response gene controlling cellular immunity against tumor-specific antigens. Analysis by tumor histology demonstrated that this resistance was significant for both squamous carcinoma and adenocarcinoma. Since the frequencies of W-19 and HL-A5 were significantly increased over the noncancer control population only for the cured patients, the presence of these antigens probably does not prevent the development of bronchogenic carcinoma. The relationship of W-19 and HL-A5 with prolonged survival in bronchogenic carcinoma might be related simply to the inclusion, albeit inadvertently, of patients with less advanced tumor into these HL-A groups. Even if analysis of the patient groups by tumor stage demonstrated that this were true, however, it is probable that whatever mechanism W-19 and HL-A5 manifest to confer the hypothesized resistance to tumor dissemination would appear initially not as patient survival but perhaps as less involvement of regional lymph nodes or the absence of distant tumor spread. There is, however, no way to control when, during tumor growth or dissemination, the patient will present himself for evaluation. It is necessary then to examine the prospective patient groups for those factors generally considered to be related to prognosis for bronchogenic carcinoma: pleural invasion, vascular invasion, degree of histologic differentiation, lymph node involvement, and distant spread of tumor (17) . From table 4, it is apparent that each prospective group was roughly comparable in the percentage of patients who were operable, who had lobectomies and pneumonectomies, and who were inoperable because of regional spread of tumors. Although there were fewer unresectable patients with W-19 and HL-A5, more of them had distant metastases. Therefore, no bias related to inclusion of patients with less advanced tumors into the W-19 or HL-A5 group existed to explain the prolonged survival observed in association with these two antigens. Our findings must be considered as preliminary. It remains for a prospective study, incorporating larger numbers of bronchogenic carcinoma patients who are followed over a longer period, to confirm the relationship of W-19 and HL-A5 with improved survival in bronchogenic carcinoma.
